Physician profile
Yulia Neyman
NPI 1982858031
$6,876.86
in general payments reported to CMS, 2019-2025
26 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.17 · 2020: $40.32 · 2021: $23.56 · 2022: $1,126 · 2023: $1,535 · 2024: $2,098 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,619.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,756.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,148.33 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,106.93 | 2022-2025 | |
| Pfizer INC. | $810.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $494.73 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $337.57 | 2022 | |
| Glaxosmithkline, LLC. | $195.25 | 2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $165.82 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.12 | 2024-2025 | Caplyta |
| Bausch Health US, LLC | $108.91 | 2022-2023 | Aplenzin |
| Sumitomo Pharma America, INC. | $102.91 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $57.39 | 2019-2022 | |
| Lundbeck LLC | $54.74 | 2024-2025 | Rexulti |
| Amgen INC. | $50.03 | 2025 | Repatha |
| Janssen Pharmaceuticals, INC | $46.63 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.76 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $37.51 | 2022 | |
| Organogenesis INC. | $34.95 | 2024 | Cygnus Dual |
| Abbott Laboratories | $32.30 | 2025 | Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.88 | 2024-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $21.92 | 2024 | Uzedy |
| Dynavax Technologies Corporation | $20.75 | 2019 | |
| Inspire Medical Systems, INC. | $20.06 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $19.39 | 2019 | |
| Hologic Sales and Service, LLC | $18.29 | 2020 | |
| Phadia US INC. | $17.05 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yulia Neyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.